Japan Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2025-2033

Description

Japan cancer biomarkers market size reached USD 1,252.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,621.3 Million by 2033, exhibiting a growth rate (CAGR) of 11.2% during 2025-2033. The increasing cases of cancer, coupled with the rising need for effective diagnostic and monitoring tools to significantly improve the chances of successful treatment and better patient outcomes, are driving the market.

Cancer biomarkers are molecules or substances found in the body that can indicate the presence of cancer or provide information about its characteristics. These biomarkers are typically detected through blood tests, tissue samples, or imaging studies. They play a crucial role in cancer diagnosis, prognosis, and treatment. Biomarkers can include proteins, genes, hormones, or even specific cellular changes. By analyzing their levels or activity, healthcare professionals can identify the type of cancer, its stage, and its potential aggressiveness. This information helps in tailoring treatment plans, monitoring disease progression, and assessing treatment effectiveness. Cancer biomarkers also have a significant impact on personalized medicine, enabling doctors to choose the most appropriate therapies for individual patients. Additionally, they aid in cancer research, facilitating the development of new drugs and therapies. Overall, cancer biomarkers are essential tools in the fight against cancer, contributing to early detection, precise treatment, and improved patient outcomes.

Japan Cancer Biomarkers Market Trends:

The cancer biomarkers market in Japan is driven by several key factors that collectively contribute to its growth and significance in the field of oncology. Firstly, advancements in molecular biology and genomics have paved the way for the identification of novel biomarkers that can aid in early cancer detection and prognosis. Moreover, the increasing prevalence of cancer in Japan is a major driver, as there is a growing need for accurate and efficient diagnostic tools to combat this regional health challenge. Furthermore, the development of targeted therapies and personalized medicine approaches has accentuated the demand for biomarkers. These biomarkers assist in tailoring treatment plans to individual patients, improving the overall efficacy of cancer treatments while minimizing adverse effects. Additionally, the rise in R&D activities in the pharmaceutical and biotechnology sectors has spurred investments in biomarker discovery and validation, further propelling market growth. Moreover, the widespread adoption of liquid biopsy techniques for non-invasive biomarker detection, as they offer a less invasive alternative to traditional tissue biopsies, is expected to drive the cancer biomarkers market in Japan during the forecast period.

Japan Cancer Biomarkers Market Segmentation:

Profiling Technology Insights:

Omic Technologies
Imaging Technologies
Immunoassays
Cytogenetics

Biomolecule Insights:

Genetic Biomarkers
Protein Biomarkers
Glyco-Biomarkers

Cancer Type Insights:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Application Insights:

Diagnostics
Prognostics
Risk Assessment
Drug Discovery and Development
Others

End User Insights:

Hospitals
Academic and Research Institutions
Ambulatory Surgical Centers
Diagnostic Laboratories
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cancer biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cancer biomarkers market?
What is the breakup of the Japan cancer biomarkers market on the basis of profiling technology?
What is the breakup of the Japan cancer biomarkers market on the basis of biomolecule?
What is the breakup of the Japan cancer biomarkers market on the basis of cancer type?
What is the breakup of the Japan cancer biomarkers market on the basis of application?
What is the breakup of the Japan cancer biomarkers market on the basis of end user?
What are the various stages in the value chain of the Japan cancer biomarkers market?
What are the key driving factors and challenges in the Japan cancer biomarkers?
What is the structure of the Japan cancer biomarkers market and who are the key players?
What is the degree of competition in the Japan cancer biomarkers market?

Product Code: SR112024A18702

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cancer Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Cancer Biomarkers Market - Breakup by Profiling Technology

6.1 Omic Technologies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Imaging Technologies
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Immunoassays
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Cytogenetics
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)

7 Japan Cancer Biomarkers Market - Breakup by Biomolecule

7.1 Genetic Biomarkers
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Protein Biomarkers
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Glyco-Biomarkers
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)

8 Japan Cancer Biomarkers Market - Breakup by Cancer Type

8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Colorectal Cancer
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Prostate Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Stomach Cancer
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)
8.6 Others
- 8.6.1 Historical and Current Market Trends (2019-2024)
- 8.6.2 Market Forecast (2025-2033)

9 Japan Cancer Biomarkers Market - Breakup by Application

9.1 Diagnostics
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Prognostics
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Risk Assessment
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Drug Discovery and Development
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
9.5 Others
- 9.5.1 Historical and Current Market Trends (2019-2024)
- 9.5.2 Market Forecast (2025-2033)

10 Japan Cancer Biomarkers Market - Breakup by End User

10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
10.2 Academic and Research Institutions
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
10.3 Ambulatory Surgical Centers
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
10.4 Diagnostic Laboratories
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2019-2024)
- 10.4.3 Market Forecast (2025-2033)
10.5 Others
- 10.5.1 Historical and Current Market Trends (2019-2024)
- 10.5.2 Market Forecast (2025-2033)

11 Japan Cancer Biomarkers Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Cancer Biomarkers Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis